DAX WOLFORD: Open Payments
NPI 1851742100 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$25,457 in 124 payments from 13 companies in 2025. Trend: 2023 $1,587 · 2024 $2,019 · 2025 $25,457
Speaker / faculty: $17,280Consulting: $2,970Travel & lodging: $2,877Food & beverage: $2,330
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 67 | $24,016 |
| Alkermes, Inc. | 13 | $414 |
| E.R. Squibb & Sons, L.L.C. | 14 | $390 |
| ABBVIE INC. | 13 | $287 |
| Otsuka America Pharmaceutical, Inc. | 4 | $96 |
| Axsome Therapeutics, Inc. | 3 | $60 |
| Teva Pharmaceuticals USA, Inc. | 3 | $56 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Bausch Health US, LLC | 1 | $25 |
Products named: CAPLYTA, COBENFY, ARISTADA, VRAYLAR, LYBALVI, Auvelity, REXULTI, ABILIFY ASIMTUFII.
Industry payments across NV — which companies pay providers there.
